Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBITDA (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBITDA for 4 consecutive years, with -$2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 16.29% to -$2.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$10.2 million, a 26.58% decrease, with the full-year FY2024 number at -$8.8 million, down 13.58% from a year prior.
  • EBITDA was -$2.2 million for Q3 2025 at bioAffinity Technologies, up from -$2.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$684119.0 in Q2 2022 to a low of -$2.9 million in Q4 2024.
  • A 4-year average of -$1.9 million and a median of -$1.9 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 156.88% in 2023, then grew 14.87% in 2024.
  • bioAffinity Technologies' EBITDA stood at -$1.6 million in 2022, then plummeted by 34.02% to -$2.2 million in 2023, then crashed by 33.44% to -$2.9 million in 2024, then increased by 22.57% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's EBITDA are -$2.2 million (Q3 2025), -$2.5 million (Q2 2025), and -$2.6 million (Q1 2025).